Contact Us:

Fina Biosolutions is Pleased to Offer CRM197

Fina Biosolutions is pleased to offer EcoCRMTM, economical CRM197 from E. coli, to the research and vaccine manufacturing community. CRM197, a genetically detoxified diphtheria toxin, is widely used as a carrier protein in conjugate vaccines. Effective conjugate vaccines against Streptococcus pneumoniae, Haemophilus influenzae band Neisseria meningitidis is […]

Andrew Lees Named to The Power List 2016

Dr. Andrew Lees, founder and Chief Scientific Officer of Fina Biosolutions, has been named to The Power List 2016 – the Top 100 most influential people in the world of drug development and manufacture. “My most significant contribution is the development of CDAP chemistry for conjugate vaccines,” […]

Now Available: A Comprehensive Review of the Uses of Antibody-dextran Conjugates by Dr. Snapper

This technical paper by presents an overview of the development and applications of antibody dextran conjugates. Fina Biosolutions provides anti-IgD and anti-IgM dextrans (mouse and human) as well as other conjugates. Andrew Lees, Scientific Director of Fina Biosolutions, has been synthesizing antibody-dextran conjugates for over 25 years. […]

Fina CEO Andrew Lees Honored by Harvey Mudd College

An esteemed research scientist and world-recognized leader in vaccine development, Andrew Lees founded Fina BioSolutions, a company committed to eliminating vaccine-preventable deaths of infants and children in emerging-market countries. With major partners in China and India, Lees is helping to create locally produced, affordable vaccines worldwide. Lees […]

BIO2015 Interview with Fina Biosolutions

SNNLive spoke with Andrew Lees, Ph.D., Scientific Director of Fina Biosolutions LLC at the BioMaryland Booth at BIO International 2015 in Philadelphia, PA.

Andrew Lees to Give Keynote Presentation at 10th Global Summit and Expo on Vaccines & Vaccination in Rome

Dr. Lees will discuss the challenges of developing and manufacturing affordable conjugate vaccines.  He will review how efficient conjugation chemistry and affordable carrier protein can help reduce manufacturing costs.  

Characterization of Fina Biosolutions’ Amino-Dextran

Comparison with Other Commercially Available Amino Dextrans The performance of AmDex in any application depends on its homogeneity and purity. The low percent dextran found in competitor AmDex means that the actual price of their amino dextran is significantly higher than the listed price per gram. In […]


  • About FinaBio
    Characterization of Fina Biosolutions’ Amino-Dextran
  • About FinaBio


9430 Key West Ave., Suite 200
Rockville, MD 20850
877-346-2246 (877-FinaBio)
301-633-0464 (Andrew Lees, Scientific Director)

About Us

Fina Biosolutions, LLC was founded in 2006 by Dr. Andrew Lees with an initial focus on helping emerging market vaccine manufacturers learn to make affordable conjugate vaccines. FinaBio has since grown to offer a variety of bioconjugation and protein services. The company is located in the heart of Maryland’s biotechnology corridor.